Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARa in ApoE(-/-) mice

Man, Bin1,2; Hu, Cuilin4; Yang, Guangyan3; Xiang, Jiaqing3; Yang, Shu3; Ma, Chuanrui1,2

2022-10-08

10.1016/j.bbrc.2022.07.072

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   Impact Factor & Quartile

0006-291X

1090-2104

Cardiovascular disease caused by atherosclerosis is a leading cause of morbidity and mortality worldwide. Diabetes is a major independent risk factor for the development of atherosclerotic cardiovascular diseases. Diabetic atherosclerosis is characterized by hyperglycemia, hyperinsulinemia, and dyslipidemia. These multiple pathological factors can induce oxidative stress, inflammation, and vascular dysfunction, which can initiate and accelerate atherogenesis. Therefore, the strategy to control the development of diabetic atherosclerosis is beneficial to the patients. Berberine is one of the most promising natural products that feature significant beneficial properties on lipid and glucose metabolism, indicating the potential to improve diabetic atherosclerosis. However, the effect and underlying mechanism against diabetic atherosclerosis remain unclear. In this study, HFD and STZ were used to induce diabetic atherosclerosis in apoE(-/-) mice, which was followed by berberine administration. Subsequently, the degree of atherosclerotic plaque, plaque stability, and lipid and glucose metabolism were determined. In addition, the underlying mechanism was revealed by in vitro and in vivo experiments. We observed that berberine improved the dysfunction of lipid and glucose metabolism, and inhibited vascular inflammation, which reduced atherogenesis and plaque vulnerability. Mechanistically, berberine stimulated KLF16 and PPARa expression in vivo and in vitro, and activation of PPARa by berberine was through enhancing KLF16 expression and nuclear translocation. Collectively, berberine can attenuate diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARa, suggesting that KLF16 is a new target of berberine and enhancing KLF16 by berberine is an efficient strategy for alleviating diabetic atherosclerosis. (C) 2022 Elsevier Inc. All rights reserved.

Berberine KLF16 PPAR alpha Lipid and glucose dysfunction Inflammation Diabetic atherosclerosis

SCI

English

Corresponding

research project of the Tianjin education commission[2019KJ044]

Biochemistry & Molecular Biology ; Biophysics

Biochemistry & Molecular Biology ; Biophysics

WOS:000852817200010

ACADEMIC PRESS INC ELSEVIER SCIENCE

BIOLOGY & BIOCHEMISTRY

Web of Science

1.Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin, Peoples R China
2.Natl Clin Res Ctr Chinese Med Acupuncture & Moxib, Taipei, Taiwan
3.Southern Univ Sci & Technol, Shenzhen Peoples Hosp, Jinan Univ, Affiliated Hosp 1,Dept Geriatr,Clin Med Coll 2, Shenzhen 518020, Guangdong, Peoples R China
4.Guangdong Med Univ, Affiliated Hosp, Guangzhou, Guangdong, Peoples R China

Man, Bin,Hu, Cuilin,Yang, Guangyan,et al. Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARa in ApoE(-/-) mice[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,2022,624.

Man, Bin,Hu, Cuilin,Yang, Guangyan,Xiang, Jiaqing,Yang, Shu,&Ma, Chuanrui.(2022).Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARa in ApoE(-/-) mice.BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,624.

Man, Bin,et al."Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARa in ApoE(-/-) mice".BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 624(2022).